|Day Low/High||13.28 / 13.83|
|52 Wk Low/High||5.14 / 16.59|
Eligible Patients to be Directed to Epizyme's Ongoing Phase 2 Clinical Trial of Tazemetostat in Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Sangamo Therapeutics, Epizyme and Revance were among the biotech stock movers in premarket trading on June 21.
Investors in Epizyme Inc. saw new options begin trading this week, for the February 2018 expiration.
AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.
Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat
Epizyme, Alexion Pharmaceuticals and XBiotech were among the biotech stock movers premarket trading on June 14.
Investors in Epizyme Inc. saw new options become available this week, for the July 21st expiration.
Management to Host Conference Call on May 18, 2017 at 8:30 a.m. ET
Dr. Copeland to Remain a Key Advisor to Epizyme Following Transition
Investors in Epizyme Inc. saw new options begin trading this week, for the April 21st expiration.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Epizyme Inc. saw new options begin trading this week, for the August 18th expiration.
Investors considering a purchase of Epizyme Inc. shares, but cautious about paying the going market price of $11.80/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.